Equity Profile

TGTX

TG Therapeutics, Inc.

Health CareBiotechnology$8.4B

Mar8Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EST

Company Snapshot

TG Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with cancer and autoimmune diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and financial health, and it will be closely watched this quarter.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market performance and acceptance of its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TGTX Q2-2026 Earnings Preview

Context

Company Snapshot

TG Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with cancer and autoimmune diseases. With a market cap of $8 billion, its advancements in treatment options could significantly impact patient care and the healthcare sector as a whole.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+113.34%

Avg Stock Reaction

+1.32%

Last Quarter Recap

In Q1-2026, TG Therapeutics reported an EPS of $0.12, which was significantly below the expected $0.23, leading to a 16.26% stock increase the following day. This indicates that despite missing expectations, investors reacted positively, possibly due to other underlying factors.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for TG Therapeutics are mixed, as the company has a history of both beating and missing EPS estimates. Investors will be keen to see if the company can regain confidence after recent disappointments.

Bull Case

The optimistic view hinges on the potential for strong revenue growth and improved EPS, which could signal successful adoption of their therapies in the market.

Bear Case

Conversely, if the company continues to miss earnings expectations, it could lead to further declines in investor confidence and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to past estimates?

Given the company's recent history of missing EPS estimates, this number will be crucial in assessing whether TG Therapeutics can regain investor confidence.

What insights can management provide about revenue growth from their latest therapies?

Understanding revenue growth will help investors gauge market acceptance and the overall success of the company's product pipeline.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for TG Therapeutics to turn around its earnings trajectory, especially given the recent positive stock reactions despite misses.

Supporting Evidence

The stock has shown resilience with positive reactions even after disappointing earnings, indicating underlying investor confidence.

Options pricing suggests a lower expected move compared to historical averages, which may not reflect the company's potential for a surprise.

The recent history of significant EPS surprises indicates that the company could outperform expectations.

Key Risk

If the EPS comes in above $0.25, it could shift the narrative significantly, leading to a re-evaluation of the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical for determining the company's trajectory, especially after a series of earnings misses.

Bull Confirmed If

An EPS of $0.25 or higher would confirm the bull case, indicating a strong recovery in earnings.

Bear Confirmed If

An EPS below $0.10 would confirm the bear case, suggesting ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±3.57%

Historical Avg

±12.3%

Pricing cheap

The options market is pricing in a relatively modest move of about 3.57%, suggesting that traders expect limited volatility around the earnings report.

Options are pricing ±3.6% while TGTX has averaged ±12.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

59.8%

Calls (49K)P/C Ratio: 0.50Puts (29K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing cheap setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If TG Therapeutics beats expectations, history suggests a potential stock increase of around 10.28%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

Should the company miss expectations again, history indicates a likely decline of about 4.05%, raising concerns about the company's growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the adoption rates of TG Therapeutics' therapies in the market.
2Management's commentary on future revenue projections and growth strategies.
3Insights into any new clinical trials or product developments that could impact earnings.
4Discussion on competitive landscape and how TG Therapeutics plans to differentiate itself.
5Any guidance on operational efficiencies or cost management strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Ross Stores, Inc.

Company Snapshot

TG Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with cancer and autoimmune diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and financial health, and it will be closely watched this quarter.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market performance and acceptance of its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TGTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+113.34%

Avg Stock Reaction

+1.32%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

The optimistic view hinges on the potential for strong revenue growth and improved EPS, which could signal successful adoption of their therapies in the market.

Bear Case

Conversely, if the company continues to miss earnings expectations, it could lead to further declines in investor confidence and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to past estimates?

Given the company's recent history of missing EPS estimates, this number will be crucial in assessing whether TG Therapeutics can regain investor confidence.

What insights can management provide about revenue growth from their latest therapies?

Understanding revenue growth will help investors gauge market acceptance and the overall success of the company's product pipeline.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for TG Therapeutics to turn around its earnings trajectory, especially given the recent positive stock reactions despite misses.

Supporting Evidence

The stock has shown resilience with positive reactions even after disappointing earnings, indicating underlying investor confidence.

Options pricing suggests a lower expected move compared to historical averages, which may not reflect the company's potential for a surprise.

The recent history of significant EPS surprises indicates that the company could outperform expectations.

Key Risk

If the EPS comes in above $0.25, it could shift the narrative significantly, leading to a re-evaluation of the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical for determining the company's trajectory, especially after a series of earnings misses.

Bull Confirmed If

An EPS of $0.25 or higher would confirm the bull case, indicating a strong recovery in earnings.

Bear Confirmed If

An EPS below $0.10 would confirm the bear case, suggesting ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±3.57%

Historical Avg

±12.3%

Pricing cheap

The options market is pricing in a relatively modest move of about 3.57%, suggesting that traders expect limited volatility around the earnings report.

Options are pricing ±3.6% while TGTX has averaged ±12.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

59.8%

Calls (49K)P/C Ratio: 0.50Puts (29K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing cheap setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If TG Therapeutics beats expectations, history suggests a potential stock increase of around 10.28%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

Should the company miss expectations again, history indicates a likely decline of about 4.05%, raising concerns about the company's growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the adoption rates of TG Therapeutics' therapies in the market.
2Management's commentary on future revenue projections and growth strategies.
3Insights into any new clinical trials or product developments that could impact earnings.
4Discussion on competitive landscape and how TG Therapeutics plans to differentiate itself.
5Any guidance on operational efficiencies or cost management strategies.